Steven Cohen's FULC Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 2.07 M shares of Fulcrum Therapeutics, Inc. (FULC) worth $15.91 M, representing 0.02% of the portfolio. First purchased in 2020-Q2, this medium-term investment has been held for 20 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in FULC, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 2.64 M shares. Largest reduction occurred in Q3 2023, reducing 1.9 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Fulcrum Therapeutics (FULC) Holding Value Over Time
Track share changes against reported price movement
Quarterly Fulcrum Therapeutics (FULC) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -323,377 | Reduce 13.48% | 2.07 M | $7.67 |
| Q4 2025 | +2.4 M | New Buy | 2.4 M | $11.31 |
| Q3 2025 | -498,219 | Sold Out | 0 | $0.00 |
| Q2 2025 | +498,219 | New Buy | 498,219 | $6.88 |
| Q2 2024 | -223,400 | Sold Out | 0 | $0.00 |
| Q1 2024 | +223,400 | New Buy | 223,400 | $9.44 |
| Q3 2023 | -1.9 M | Sold Out | 0 | $0.00 |
| Q2 2023 | -743,704 | Reduce 28.13% | 1.9 M | $3.30 |
| Q1 2023 | +2.64 M | New Buy | 2.64 M | $2.85 |
| Q4 2022 | -1.49 M | Sold Out | 0 | $0.00 |
| Q3 2022 | -494,797 | Reduce 24.88% | 1.49 M | $8.09 |
| Q2 2022 | +1.66 M | Add 511.94% | 1.99 M | $4.90 |
| Q1 2022 | -180,655 | Reduce 35.73% | 325,000 | $23.65 |
| Q4 2021 | +365,655 | Add 261.18% | 505,655 | $17.69 |
| Q3 2021 | -412,885 | Reduce 74.68% | 140,000 | $28.21 |
| Q2 2021 | -22,361 | Reduce 3.89% | 552,885 | $10.48 |
| Q1 2021 | -762,877 | Reduce 57.01% | 575,246 | $11.78 |
| Q4 2020 | -171,877 | Reduce 11.38% | 1.34 M | $11.71 |
| Q3 2020 | +1.25 M | Add 479.22% | 1.51 M | $7.93 |
| Q2 2020 | +260,697 | New Buy | 260,697 | $18.29 |
Steven Cohen's Fulcrum Therapeutics Investment FAQs
Steven Cohen first purchased Fulcrum Therapeutics, Inc. (FULC) in Q2 2020, acquiring 260,697 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Fulcrum Therapeutics, Inc. (FULC) for 20 quarters since Q2 2020.
Steven Cohen's largest addition to Fulcrum Therapeutics, Inc. (FULC) was in Q1 2023, adding 2,643,672 shares worth $7.53 M.
According to the latest 13F filing for Q1 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 2,074,855 shares of Fulcrum Therapeutics, Inc. (FULC), valued at approximately $15.91 M.
As of the Q1 2026 filing, Fulcrum Therapeutics, Inc. (FULC) represents approximately 0.02% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Fulcrum Therapeutics, Inc. (FULC) was 2,643,672 shares, as reported at the end of Q1 2023.